Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
Talal El Zarif(Yale University), Danai Dima(Fred Hutch Cancer Center), Nerea Lopetegui‐Lia(Cleveland Clinic), Javier Baena(Research Institute Hospital 12 de Octubre), Ahmad Al‐Hader(Indiana University Health), Robert A. Baiocchi(The Ohio State University Wexner Medical Center), Aakriti Arora(Washington Hospital), Taylor K. Nonato(University of California San Diego), Bailey G. Fitzgerald(Icahn School of Medicine at Mount Sinai), Michael Lorentsen(University of North Carolina at Chapel Hill), Batool Abu Ghazal(The University of Kansas Cancer Center), Edward El‐Am(Mayo Clinic in Arizona), Adi Diab(Cleveland Clinic), Claire Drolen(University of California, Los Angeles), Veli Bakalov(Allegheny Health Network), Caroline A. Nebhan(VA Tennessee Valley Healthcare System), Ankit Mangla(University Hospitals Seidman Cancer Center), Aarthi Rajkumar(University Hospitals Seidman Cancer Center), Mingjia Li(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Tarek Haykal(Duke Medical Center), Anwaar Saeed(University of Pittsburgh), Arjun Mittra(The Ohio State University), Alexandra Drakaki(University of California, Los Angeles), Evan Hall(Stanford University), Tarek H. Mouhieddine(Icahn School of Medicine at Mount Sinai), Frank Aboubakar Nana(Cliniques Universitaires Saint-Luc), Rana R. McKay(University of California San Diego), Neil J. Shah(Memorial Sloan Kettering Cancer Center), Alessio Cortellini(Campus Bio Medico University Hospital), Elie Kozaily(Indiana University Health), Elio Adib(Dana-Farber Brigham Cancer Center), Anand Bankapur(Research Institute Hospital 12 de Octubre), Amin H. Nassar(Brigham and Women's Hospital), Nathan Bahary(University of Pittsburgh Medical Center), Michael A. Morse(Duke Medical Center), Christopher Dittus(Palmetto Hematology Oncology), Melissa G. Lechner(University of California, Los Angeles), Alessia Dalla Pria(Hammersmith Hospital), Vishal Shah(Mayo Clinic Hospital), Wassim Abdallah(Emory University), Adewunmi Falohun(The University of Texas MD Anderson Cancer Center), Nazlı Dizman(City Of Hope National Medical Center), Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jiaming Huang(Dana-Farber Cancer Institute), Chul Kim(Georgetown University), P Rubinstein(John H. Stroger, Jr. Hospital of Cook County), Alexandra Reed(Research Institute Hospital 12 de Octubre), Noha Abdel‐Wahab(The University of Texas MD Anderson Cancer Center), Parminder Singh(Mayo Clinic Hospital), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Cited by 69
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k